Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus docetaxel as second-line therapy for advanced lung squamous carcinoma
ChiCTR-OPC-17011378Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- May 2017
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib and docetaxel in Pulmonary squamous cell carcinoma, sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: progression-free survival. Started May 2017; status: recruiting.
02
Drugs
Rivoceranibdocetaxel
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on ChiCTR-OPC-17011378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-17011378.